Floatz logo

Trebananib

Recurrent Brain Neoplasm

National Cancer Institute (NCI)protein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

62 Active assets in the Recurrent Brain Neoplasm cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 2BBB
Temsirolimus
M.D. Anderson Cancer Center
Phase 2BBB
Sorafenib
National Cancer Institute (NCI)
Phase 2BB
Bxcl501
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4BB
Nivolumab
InSightec
Phase 3BB

View all 50 →

Same molecule, other indications

Trebananib is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
primary peritoneal carcinomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →